CoChat

Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Lyme disease is a tick-borne illness caused by the bacterium Borrelia burgdorferi , and approximately 10 to 20% of patients report persistent symptoms lasting months to years despite appropriate treatment with antibiotics. To gain insights into the molecular basis of acute Lyme disease and the ensuing development of post-treatment symptoms, we conducted a longitudinal transcriptome study of 29 Lyme disease patients (and 13 matched controls) enrolled at the time of diagnosis and followed for up to 6 months. The differential gene expression signature of Lyme disease following the acute phase of infection persisted for at least 3 weeks and had fewer than 44% differentially expressed genes (DEGs) in common with other infectious or noninfectious syndromes. Early Lyme disease prior to antibiotic therapy was characterized by marked upregulation of Toll-like receptor signaling but lack of activation of the inflammatory T-cell apoptotic and B-cell developmental pathways seen in other acute infectious syndromes. Six months after completion of therapy, Lyme disease patients were found to have 31 to 60% of their pathways in common with three different immune-mediated chronic diseases. No differential gene expression signature was observed between Lyme disease patients with resolved illness to those with persistent symptoms at 6 months post-treatment. The identification of a sustained differential gene expression signature in Lyme disease suggests that a panel of selected human host-based biomarkers may address the need for sensitive clinical diagnostics during the “window period” of infection prior to the appearance of a detectable antibody response and may also inform the development of new therapeutic targets. IMPORTANCE Lyme disease is the most common tick-borne infection in the United States, and some patients report lingering symptoms lasting months to years despite antibiotic treatment. To better understand the role of the human host response in acute Lyme disease and the development of post-treatment symptoms, we conducted the first longitudinal gene expression (transcriptome) study of patients enrolled at the time of diagnosis and followed up for up to 6 months after treatment. Importantly, we found that the gene expression signature of early Lyme disease is distinct from that of other acute infectious diseases and persists for at least 3 weeks following infection. This study also uncovered multiple previously undescribed pathways and genes that may be useful in the future as human host biomarkers for diagnosis and that constitute potential targets for the development of new therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.00100-16

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Schematic description of study design. (A) Timeline of clinical evaluation and PBMC sampling. (B) Flowchart of the number of patients with resolved illness or persistent symptoms. Abbreviations: non-PTLDS, post-treatment Lyme disease symptoms and no functional decline; PTLDS, PTLDS with a functional decline.
FIG 1 Schematic description of study design. (A) Timeline of clinical evaluation and PBMC sampling. (B) Flowchart of the number of patients with resolved illness or persistent symptoms. Abbreviations: non-PTLDS, post-treatment Lyme disease symptoms and no functional decline; PTLDS, PTLDS with a functional decline.CC BY · PubMed Central
FIG 2 Longitudinal differential gene expression and pathway analysis of Lyme disease. (A) Bar chart of the numbers of genes found to be upregulated or downregulated at Lyme disease diagnosis (V1), 3 weeks post-treatment (V2, after a standard course of antibiotics), and 6 months post-treatment (V5). (B) Venn diagram representing the number of DEGs between Lyme disease patients and controls at three time points. (C) Principal component analysis (PCA) of Lyme disease patients and controls at three time points on the basis of 1,759 unique DEGs identified at V1, V2, and V5. The asterisk represents a subject in the control group who looks like an outlier in the PCA plot but is not shown to be an outlier by PCA analysis of the control samples (see Fig. S2 in the supplemental material). Note that the PC3 axis in the PCA plot accounts for only 8% of the variance in the data set. (D to F) Top 10 disease and functional categories (D), top 10 canonical pathways (E), and top 10 upstream regulators (excluding drug categories) (F) predicted to be involved in Lyme disease at (V1, V2, and V5) with categories, pathways, and genes ranked by the negative log of the P value of the enrichment score. The color scheme is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray. The red line represents the designated significance threshold (P < 0.05).
FIG 2 Longitudinal differential gene expression and pathway analysis of Lyme disease. (A) Bar chart of the numbers of genes found to be upregulated or downregulated at Lyme disease diagnosis (V1), 3 weeks post-treatment (V2, after a standard course of antibiotics), and 6 months post-treatment (V5). (B) Venn diagram representing the number of DEGs between Lyme disease patients and controls at three time points. (C) Principal component analysis (PCA) of Lyme disease patients and controls at three time points on the basis of 1,759 unique DEGs identified at V1, V2, and V5. The asterisk represents a subject in the control group who looks like an outlier in the PCA plot but is not shown to be an outlier by PCA analysis of the control samples (see Fig. S2 in the supplemental material). Note that the PC3 axis in the PCA plot accounts for only 8% of the variance in the data set. (D to F) Top 10 disease and functional categories (D), top 10 canonical pathways (E), and top 10 upstream regulators (excluding drug categories) (F) predicted to be involved in Lyme disease at (V1, V2, and V5) with categories, pathways, and genes ranked by the negative log of the P value of the enrichment score. The color scheme is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray. The red line represents the designated significance threshold (P < 0.05).CC BY · PubMed Central
FIG 3 Heat maps of disease and functional categories predicted to be involved in Lyme disease. Shown are heat maps at V1, V2, and V5. The color scheme shown is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray.
FIG 3 Heat maps of disease and functional categories predicted to be involved in Lyme disease. Shown are heat maps at V1, V2, and V5. The color scheme shown is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray.CC BY · PubMed Central
FIG 4 Comparison of the Lyme disease transcriptome with transcriptomes corresponding to other clinical illnesses or cell models. (A) Bar chart of the percentages of overlapping DEGs and canonical pathways between acute Lyme disease at V1 and other infectious diseases or in vitro cell culture models of infection. (B) Bar chart of the negative log of the P value of the enrichment score corresponding to selected pathways predicted to be involved in acute Lyme disease at V1 compared to other bacterial and viral infections. (C) Bar chart of the percentage of overlapping DEGs and canonical pathways between Lyme disease patients at V5 and three chronic and/or autoimmune syndromes (SLE, CFS, and RA). (D) Bar chart of the negative log of the P value of the enrichment score from selected pathways predicted to be involved in Lyme disease 6 months post-treatment (V5) compared to those from other chronic and/or autoimmune syndromes. The color scheme depicted is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray. The red line represents a P value significance threshold of 0.05.
FIG 4 Comparison of the Lyme disease transcriptome with transcriptomes corresponding to other clinical illnesses or cell models. (A) Bar chart of the percentages of overlapping DEGs and canonical pathways between acute Lyme disease at V1 and other infectious diseases or in vitro cell culture models of infection. (B) Bar chart of the negative log of the P value of the enrichment score corresponding to selected pathways predicted to be involved in acute Lyme disease at V1 compared to other bacterial and viral infections. (C) Bar chart of the percentage of overlapping DEGs and canonical pathways between Lyme disease patients at V5 and three chronic and/or autoimmune syndromes (SLE, CFS, and RA). (D) Bar chart of the negative log of the P value of the enrichment score from selected pathways predicted to be involved in Lyme disease 6 months post-treatment (V5) compared to those from other chronic and/or autoimmune syndromes. The color scheme depicted is based on Z scores, with activation in orange, inhibition in blue, and undetermined directionality in gray. The red line represents a P value significance threshold of 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Metadata

Authors
Bouquet, J., Soloski, M. J., Swei, A., Cheadle, C., Federman, S., Billaud, J.-N., Rebman, A. W., Kabre, B., Halpert, R., Boorgula, M., Aucott, J. N., & Chiu, C. Y.
Affiliations
  • Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA
  • Johns Hopkins University (US)
  • San Francisco State University (US)
  • University of California, San Francisco (US)
  • Qiagen Bioinformatics, Redwood City, California, USA
  • Qiagen (United States) (US)
Corresponding author
  • Aucott, John N.
  • Chiu, Charles Y.
Venue
mBio
Published
2016-03-02
Volume
7
Issue
1
Pages
e00100-16
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2265193578
Cited by
101
References
56
Citations by year
2026: 5 · 2025: 9 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 14 · 2020: 12 · 2019: 12 · 2018: 7 · 2017: 6 · 2016: 7
FWCI
10.98
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Swartz Foundation
  • Bay Area Lyme Foundation
  • Stabler Foundation
  • Lyme Research Alliance
  • Lyme Disease Research Foundation, Inc.
  • Office of Extramural Research, National Institutes of Health (HL105704, P30-AR05350)
  • Abbott Laboratories
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Vector-borne infectious diseases
  • Health Sciences › Medicine › Infectious Diseases › Brucella: diagnosis, epidemiology, treatment
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords
Lyme disease, Borrelia burgdorferi, post-treatment Lyme disease syndrome, differential gene expression, host immune response, Toll-like receptor signaling, persistent symptoms, host biomarkers, T cell apoptosis, B cell development, tick-borne diseases
MeSH terms
Adult, Animals, Female, Humans, Lyme Disease, Male, Middle Aged, United States, Biomarkers, Gene Expression Profiling, Borrelia burgdorferi, Metabolic Networks and Pathways, High-Throughput Nucleotide Sequencing, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.